U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511062) titled 'Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML' on March 25.
Brief Summary: Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
Study Start Date: Aug. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
TP53 Gene Mutation
Intervention:
DRUG: Decitabine
20mg/m2/d x5 days (induction & consolidation)
DRUG: Venetoclax
400mg/d x14 days (induction); 400mg/d x7 days (consolidation)
DRUG: Axatilimab
Dose escalation, given on Days 1 and 15 of each cycle
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Northside Hospital, Inc....